Plasma kinetics of 125I-labelled amyloid P component in beta 2M amyloidosis: a possible approach to quantitate disease activity.
Dialysis amyloidosis is one of the most incapacitating complications of long-term dialysis treatment. Quantitative assessment of amyloid deposition using radiolabelled tracers has been recently proposed but convincing evidence of its validity in uraemic patients remains to be provided. We studied the plasma kinetics of i.v. administered 125I-labelled serum amyloid P component (125I-SAP) in 20 chronic haemodialysis patients compared with those of nine healthy volunteers and three non-dialysed patients with systemic amyloidosis. Plasma clearance of the tracer was abnormal in 17 of 20 dialysis patients in whom plasma radioactivity declined in a bi-exponential mode, in contrast to the single-exponential slope observed in all healthy controls. 125I-SAP plasma half-life of the second component, probably reflecting metabolic clearance, was significantly prolonged in these dialysis patients compared with the healthy controls (35.3 versus 24.6 h, P < 0.001). Among the long-term haemodialysis patients the calculated extravascular distribution of 125I-SAP was significantly greater in those with severe arthropathy than in asymptomatic patients. These findings demonstrate for the first time that SAP clearance is disturbed in haemodialysis patients due to both failing renal elimination and retention in extravascular sites. The extravascular diffusion is greatly enhanced in patients with clinical evidence of amyloidosis. Therefore the study of plasma 125I-SAP kinetics promises to be a valuable tool to quantitate the extent of amyloidosis.
Zingraff
J
J
Clinique Néphrologique and INSERM U90, Hôpital Necker, Paris, France.
Caillat-Vigneron
N
N
Ureña
P
P
Gagné
E R
ER
Bererhi
L
L
Moretti
J L
JL
Bardin
T
T
Drüeke
T B
TB
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000686:Amyloidosis / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology; D016022:Case-Control Studies; D005260:Female; D006207:Half-Life; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects; D000683:Serum Amyloid P-Component / Q000493:pharmacokinetics*; D014511:Uremia / Q000378:metabolism; D001613:beta 2-Microglobulin / Q000378:metabolism*
D007457:Iodine Radioisotopes; D000683:Serum Amyloid P-Component; D001613:beta 2-Microglobulin